MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis
NASDAQ:MDXG - Nasdaq - US6024961012 - Common Stock - Currency: USD
Overall MDXG gets a fundamental rating of 5 out of 10. We evaluated MDXG against 555 industry peers in the Biotechnology industry. MDXG is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. MDXG is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
MDXG had positive earnings in the past year.
In the past year MDXG had a positive cash flow from operations.
In multiple years MDXG reported negative net income over the last 5 years.
In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 14.86%, MDXG belongs to the best of the industry, outperforming 96.06% of the companies in the same industry.
Looking at the Return On Equity, with a value of 19.82%, MDXG belongs to the top of the industry, outperforming 96.24% of the companies in the same industry.
MDXG has a better Return On Invested Capital (14.58%) than 96.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.86% | ||
| ROE | 19.82% | ||
| ROIC | 14.58% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG has a Profit Margin of 11.40%. This is amongst the best in the industry. MDXG outperforms 93.37% of its industry peers.
MDXG has a Operating Margin of 12.86%. This is amongst the best in the industry. MDXG outperforms 94.09% of its industry peers.
MDXG's Operating Margin has been stable in the last couple of years.
With an excellent Gross Margin value of 81.94%, MDXG belongs to the best of the industry, outperforming 86.02% of the companies in the same industry.
MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.86% | ||
| PM (TTM) | 11.4% | ||
| GM | 81.94% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDXG is creating some value.
The number of shares outstanding for MDXG has been increased compared to 1 year ago.
Compared to 5 years ago, MDXG has more shares outstanding
The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 9.90 indicates that MDXG is not in any danger for bankruptcy at the moment.
MDXG has a Altman-Z score of 9.90. This is amongst the best in the industry. MDXG outperforms 86.74% of its industry peers.
The Debt to FCF ratio of MDXG is 0.29, which is an excellent value as it means it would take MDXG, only 0.29 years of fcf income to pay off all of its debts.
MDXG's Debt to FCF ratio of 0.29 is amongst the best of the industry. MDXG outperforms 95.88% of its industry peers.
MDXG has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.09, MDXG is not doing good in the industry: 64.34% of the companies in the same industry are doing better.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.29 | ||
| Altman-Z | 9.9 |
ROIC/WACC1.65
WACC8.81%
2.3 Liquidity
A Current Ratio of 4.70 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Current ratio (4.70) which is in line with its industry peers.
MDXG has a Quick Ratio of 4.13. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.13, MDXG perfoms like the industry average, outperforming 48.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.7 | ||
| Quick Ratio | 4.13 |
3. Growth
3.1 Past
MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.78%.
Looking at the last year, MDXG shows a small growth in Revenue. The Revenue has grown by 5.34% in the last year.
The Revenue has been growing slightly by 3.11% on average over the past years.
EPS 1Y (TTM)-37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)5.34%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%4.13%
3.2 Future
Based on estimates for the next years, MDXG will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.19% on average per year.
Based on estimates for the next years, MDXG will show a quite strong growth in Revenue. The Revenue will grow by 12.54% on average per year.
EPS Next Y-12.95%
EPS Next 2Y7.74%
EPS Next 3Y8.19%
EPS Next 5YN/A
Revenue Next Year8.51%
Revenue Next 2Y9.96%
Revenue Next 3Y10.14%
Revenue Next 5Y12.54%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 21.21, the valuation of MDXG can be described as rather expensive.
Based on the Price/Earnings ratio, MDXG is valued cheaper than 94.80% of the companies in the same industry.
MDXG is valuated rather cheaply when we compare the Price/Earnings ratio to 26.98, which is the current average of the S&P500 Index.
MDXG is valuated rather expensively with a Price/Forward Earnings ratio of 17.65.
93.37% of the companies in the same industry are more expensive than MDXG, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.49, MDXG is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.21 | ||
| Fwd PE | 17.65 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaply inside the industry as 95.34% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 95.52% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.59 | ||
| EV/EBITDA | 14.68 |
4.3 Compensation for Growth
The decent profitability rating of MDXG may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.74%
EPS Next 3Y8.19%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.94
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.18%
Inst Owner Change6.78%
Ins Owners1.74%
Ins Owner Change1.17%
Market Cap877.34M
Analysts81.82
Price Target12.24 (106.06%)
Short Float %3.58%
Short Ratio7.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.48%
Min EPS beat(2)-31.92%
Max EPS beat(2)6.95%
EPS beat(4)3
Avg EPS beat(4)9.74%
Min EPS beat(4)-31.92%
Max EPS beat(4)52.51%
EPS beat(8)7
Avg EPS beat(8)71.29%
EPS beat(12)9
Avg EPS beat(12)45.41%
EPS beat(16)12
Avg EPS beat(16)48.58%
Revenue beat(2)2
Avg Revenue beat(2)1.09%
Min Revenue beat(2)0.32%
Max Revenue beat(2)1.86%
Revenue beat(4)2
Avg Revenue beat(4)-0.5%
Min Revenue beat(4)-3.85%
Max Revenue beat(4)1.86%
Revenue beat(8)6
Avg Revenue beat(8)1.5%
Revenue beat(12)8
Avg Revenue beat(12)1.63%
Revenue beat(16)12
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)-10.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.6%
EPS NY rev (1m)0.61%
EPS NY rev (3m)-20.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.12%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)-0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.21 | ||
| Fwd PE | 17.65 | ||
| P/S | 2.49 | ||
| P/FCF | 13.59 | ||
| P/OCF | 13.39 | ||
| P/B | 4.33 | ||
| P/tB | 5.09 | ||
| EV/EBITDA | 14.68 |
EPS(TTM)0.28
EY4.71%
EPS(NY)0.34
Fwd EY5.67%
FCF(TTM)0.44
FCFY7.36%
OCF(TTM)0.44
OCFY7.47%
SpS2.39
BVpS1.37
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.86% | ||
| ROE | 19.82% | ||
| ROCE | 19.89% | ||
| ROIC | 14.58% | ||
| ROICexc | 27.36% | ||
| ROICexgc | 36.54% | ||
| OM | 12.86% | ||
| PM (TTM) | 11.4% | ||
| GM | 81.94% | ||
| FCFM | 18.33% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score5
Asset Turnover1.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.29 | ||
| Debt/EBITDA | 0.33 | ||
| Cap/Depr | 11.12% | ||
| Cap/Sales | 0.27% | ||
| Interest Coverage | 27.66 | ||
| Cash Conversion | 121.79% | ||
| Profit Quality | 160.71% | ||
| Current Ratio | 4.7 | ||
| Quick Ratio | 4.13 | ||
| Altman-Z | 9.9 |
F-Score5
WACC8.81%
ROIC/WACC1.65
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-12.95%
EPS Next 2Y7.74%
EPS Next 3Y8.19%
EPS Next 5YN/A
Revenue 1Y (TTM)5.34%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%4.13%
Revenue Next Year8.51%
Revenue Next 2Y9.96%
Revenue Next 3Y10.14%
Revenue Next 5Y12.54%
EBIT growth 1Y-18.47%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year25.32%
EBIT Next 3Y18.64%
EBIT Next 5YN/A
FCF growth 1Y533.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y659.04%
OCF growth 3YN/A
OCF growth 5YN/A